human umbilical cord mesenchymal stem cells (The Fifth Medical Center of the PLA General Hospital)

hUC-MSC_Prolonged refers to a specific therapeutic candidate or treatment protocol involving human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) for the treatment of acute-on-chronic liver failure (ACLF). Developed and primarily investigated by the Fifth Medical Center of the PLA General Hospital (formerly the 302 Military Hospital of China), this cell therapy utilizes the immunomodulatory and regenerative potential of MSCs. The 'Prolonged' designation typically identifies a specific dosing regimen or study arm evaluating the efficacy of multiple MSC infusions over an extended period compared to standard care or short-term protocols. The mechanism of action involves the migration of administered cells to the injured liver, where they exert anti-inflammatory effects by modulating T-cell and macrophage activity, reducing the systemic inflammatory response, and promoting hepatocyte survival and tissue repair through the secretion of paracrine factors such as hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). Clinical trials, including NCT03414099, have focused on evaluating the safety and survival benefits of this approach in patients with life-threatening liver failure.

Other names

hUC-MSCUC-MSChuman umbilical cord-derived mesenchymal stem cellsumbilical cord mesenchymal stem cells